Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Acadia Pharmaceuticals Inc (ACAD)

338 + Investors. Track Smart Money conviction in ACAD. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +5
Streak
1Q ▲
Buyers last Q
49%

Smart Money Signals — ACAD

Based on 340 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added ACAD than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
340 hedge funds hold ACAD right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +7% more funds vs a year ago

fund count last 6Q
+23 new funds entered over the past year (+7% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 49% buying

160 buying165 selling
Last quarter: 165 funds reduced or exited vs 160 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
⚠️

Fewer new buyers each quarter (-9 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 48 → 60 → 52 → 43. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

57% of holders stayed for 2+ years

■ 57% conviction (2yr+) ■ 24% medium ■ 19% new
194 out of 340 hedge funds have held ACAD for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -1%, value -18%

Value
-17%
Shares
0%
Last quarter: funds added -1% more shares while total portfolio value only changed -18%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
➡️

Steady discovery — ~43 new funds/quarter

66 → 48 → 60 → 52 → 43 new funds/Q
New funds entering each quarter: 48 → 60 → 52 → 43. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Deep conviction — 65% of holders stayed 2+ years

■ 65% veterans ■ 10% 1-2yr ■ 25% new
Of 352 current holders: 228 (65%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 25% AUM from major funds

25% from top-100 AUM funds
54 of 340 holders rank in the top 100 by AUM, accounting for 25% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ACAD

In 2026 Q1, 160 hedge funds were net buyers of ACAD (43 opened a new position, 117 added to an existing one), while 165 reduced or exited (127 trimmed, 38 sold completely) — a 49% buyer ratio, indicating roughly balanced activity. 25% of total institutional value in ACAD is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +5 funds (more new holders than closures). Total institutional holders: 340.

Hedge Fund Ownership: ACAD

How many hedge funds hold ACAD — quarterly history vs. share price
Quarterly hedge fund ownership of ACAD vs. share price

Market Analysis: ACAD

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ACAD

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Acadia Pharmaceuticals Inc (ACAD) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ACAD has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
ACAD
-5.3%
XLV
+4.9%

ACAD outperformed XLV by -10.2% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
ACAD
-1.4%
XLV
+6.0%

Since the filing became public, ACAD outperformed XLV by -7.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

29 top-rated funds 2 high-conviction
Consensus
6.4
/ 10
breadth
×
Elite
2.1
/ 10
conviction
Hedge Fund Positioning: ACAD
338 + Investors

Track Smart Money conviction in ACAD. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 338 335 0.9%
13F Shares 165M 167M -0.89%
Total Value $3.64B $4.43B -17.85%
New Positions 42 52 -10
Increased Positions 114 121 -7
Closed Positions 39 52 -13
Reduced Positions 125 118 +7
Total Calls 8 8 -
Total Puts 7 8 -12.5%
PUT/CALL Ratio 0.88 1.0 Neutral

Statistics: ACAD

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

338 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ACAD. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ACAD holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Palo Alto Investors LP 9.78% 2,872,695 $63.9M
2 Baker BROS. Advisors LP 5.48% 42,896,690 $954.9M
3 Ishara Investments LP 2.59% 123,000 $2.7M
4 Axecap Investments, LLC 2.34% 152,910 $3.4M
5 Birchview Capital, LP 2.17% 171,000 $3.8M
6 Nan Fung Group Holdings Ltd 1.89% 102,984 $2.3M
7 Braidwell LP 1.84% 2,471,199 $55.0M
8 Verdad Advisers, LP 1.71% 68,290 $1.5M
9 Rtw Investments, LP 1.58% 7,144,524 $159.0M
10 Stempoint Capital LP 1.05% 242,566 $5.4M
11 Sphera Funds Management LTD. 0.91% 256,202 $5.7M
12 Stonepine Capital Management, LLC 0.89% 100,000 $2.2M
13 Logos Global Management LP 0.83% 750,000 $16.7M
14 Frazier Life Sciences Management, L.P. 0.82% 1,438,198 $32.0M
15 Hussman Strategic Advisors, INC. 0.81% 168,000 $3.7M
16 Rice Hall James & Associates, LLC 0.77% 617,489 $13.7M
17 Tetragon Partners GP Ltd 0.62% 144,620 $3.2M
18 Virtus Advisers, LLC 0.44% 42,974 $957K
19 PSP Research LLC 0.31% 19,766 $440K
20 Phocas Financial Corp. 0.28% 81,347 $1.8M
21 Hohimer Wealth Management, LLC 0.24% 91,800 $2.0M
22 Yorktown Management & Research Co Inc 0.22% 12,050 $268K
23 Emerald Investment Advisers, LLC 0.22% 110,039 $2.4M
24 Kelsey Financial, LLC 0.19% 10,000 $223K
25 Virtus Investment Advisers, LLC 0.19% 31,095 $692K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Acadia Pharmaceuticals Inc (ACAD)

What does the Smart Money Trend signal show for ACAD?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added ACAD than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ACAD?

More sellers than buyers — 49% buying: Last quarter: 165 funds reduced or exited vs 160 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for ACAD holders?

Strong quality — 25% AUM from major funds: 54 of 340 holders rank in the top 100 by AUM, accounting for 25% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ACAD?

57% of holders stayed for 2+ years: 194 out of 340 hedge funds have held ACAD for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Acadia Pharmaceuticals Inc (ACAD) following the 2026 Q1 hedge fund 13F filings?

As of today, ACAD has moved -1.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -7.4%. Since the quarter end (March 31, 2026), ACAD has gained -5.3% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →